BRAF and melanoma: Thus, immune therapeutic agents and targeted BRAF inhibition therapy have become the mainstream in melanoma’s evolving landscape, as a higher amount of neoantigens present in these patients induces better responses to immune checkpoint inhibitors, and targeting BRAF pathway appears to have a favorable impact on immune surveillance in TME.